It is intended to evaluate the effect of a marketed cream (Alantel®) based on natural products at high concentrations for the preventive and curative treatment (early stages) of radiation-induced dermatitis in cancer patients. For this, an experimental, prospective, controlled clinical trial, with two parallel arms, double blind, multicentre, will be carried out in which doctors will recruit 78 patients aged 14 years or over in Primary Care consultations. more, diagnosed with cancer, and having received radiotherapeutic cancer treatment, being randomly assigned to the experimental group (cosmetic cream) or the control group (emollient and moisturizing cream). The main variable will be the incidence rate of mild post-translational dermatitis and its improvement or cure once it has been established.

Inclusion Criteria:

• Patients 14 years of age or older
• Diagnosed with cancer and who are or have recently received radiotherapy treatment.
• We will include patients without dermatitis or with acute dermal posttradiotherapy lesions, in grades 1 and 2.

Exclusion Criteria:

• Patients with dermal lesions in grade greater than 2.
• Skin cancer invasion or distant tumor metastasis.
• Concurrent chemotherapy with RT, severe / extensive burns, moisture, erosion or suppuration in the skin, history of connective tissue disorders, severe mental disorder (dementia, drug addiction, etc.).
• History of hypersensitivity reaction to any of the ingredients of the studio cream.
• Participants involved in other clinical trials within that month.

Double blind: both the patient and the healthcare professional do not know if the cream to be tested or the placebo is applied